Delay of surgery for DCIS ups risk for invasive breast cancer

Delay of surgery for DCIS ups risk for invasive breast cancer

(HealthDay)—For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.

William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).

The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive . Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each interval increase in delay (hazard ratio, 1.07). A longer delay to surgery was an independent predictor of invasion (odds ratio, 1.13).

"Since observation represents infinite , it suggests that observation should not yet be pursued outside of a clinical trial in patients who will tolerate excision," a coauthor said in a statement.

Explore further

Benefit of surgery for ductal carcinoma in-situ investigated

More information: Abstract/Full Text
Journal information: Annals of Surgical Oncology

Copyright © 2019 HealthDay. All rights reserved.

Citation: Delay of surgery for DCIS ups risk for invasive breast cancer (2019, October 28) retrieved 22 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors